Gliclazide
ADVERTISEMENT
- Molecular formula
- C15H21N3O6S
- CAS Number
- 21187-98-4
- IUPAC Name
- 1-cyclohexyl-3-[4-(1-hydroxyethyl)phenyl]sulfonyl-urea
- Molecular Weight
- 323.41g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.2898g/cm3
- Synonyms
- HYDROXYHEXAMIDE
Identification
Interesting facts
Interesting Facts About 1-cyclohexyl-3-[4-(1-hydroxyethyl)phenyl]sulfonyl-urea
1-cyclohexyl-3-[4-(1-hydroxyethyl)phenyl]sulfonyl-urea is a compound that belongs to a class of molecules known for their significant biological activity. Here are some fascinating aspects of this particular compound:
- Pharmaceutical Relevance: This compound is studied for its potential therapeutic applications, particularly in the field of diabetes management. Compounds with sulfonylurea structures often play a role in regulating blood sugar levels.
- Mechanism of Action: As a sulfonylurea, it is thought to stimulate insulin secretion from the pancreas. This mechanistic insight is crucial for understanding how such compounds can be employed in treatment strategies for type 2 diabetes.
- Structural Complexity: The inclusion of a cyclohexyl group and a hydroxyethylphenyl moiety contributes to its unique properties. The structure not only determines solubility and stability but also influences its binding affinities to various biological targets.
- Research Exploration: Scientists are continuously investigating this compound and its analogs for their anti-diabetic efficacy, alongside looking at possible side effects and metabolic pathways when introduced into biological systems.
- Potential Side Effects: Like many similar compounds, attention is required to monitor hypoglycemia risk, emphasizing the pharmaceutical importance of careful dosage and patient monitoring.
In summary, 1-cyclohexyl-3-[4-(1-hydroxyethyl)phenyl]sulfonyl-urea embodies the interplay between organic chemistry and medicinal applications. With ongoing research, this compound may further unveil its potential benefits and application in healthcare.